
Martin Dietrich, MD, PhD, separates an agent working in the brain from an agent acting on the brain, and explains that structural overlap in the adenosine triphosphate (ATP) binding pocket makes TRK family inhibition difficult to avoid.

Martin Dietrich, MD, PhD, separates an agent working in the brain from an agent acting on the brain, and explains that structural overlap in the adenosine triphosphate (ATP) binding pocket makes TRK family inhibition difficult to avoid.

Martin Dietrich, MD, PhD, says duration of response and progression-free survival converge in the untreated setting, because response rates approach the whole population, so the two numbers carry much the same information.

Wade Iams, MD, frames central nervous system management around radiation sparing.

Martin Dietrich, MD, PhD, says the first move at progression is to extend frontline therapy rather than abandon it, looking for oligometastatic patterns that stereotactic radiation can handle while the inhibitor continues; a patient progressing at four years with two or three new lesions is a candidate.

Wade Iams, MD, says progression-free survival (PFS) drives his frontline choice, since median overall survival remains years away in ROS1-positive advanced non-small cell lung cancer and no head-to-head comparison exists.

Wade Iams, MD, says the guidance has changed on what to do when a ROS1 result lands after chemoimmunotherapy has already started.

Wade Iams, MD, says adding RNA-based next-generation sequencing (NGS) to DNA-based NGS identifies about 15% more patients with actionable fusions, and urges clinicians to confirm whether the panel they ordered includes RNA at all, since the report rarely makes that obvious.

Dr. Monty Pal concludes the program by discussing how the treatment landscape for advanced renal cell carcinoma (RCC) may evolve as new clinical evidence emerges.

Dr. Monty Pal concludes his discussion on treatment sequencing in advanced renal cell carcinoma (RCC) by summarizing how he applies current guideline recommendations alongside individualized clinical decision making in routine practice.

Dr. Monty Pal reviews emerging clinical evidence evaluating belzutifan-based treatment strategies in advanced renal cell carcinoma (RCC), with particular focus on the LITESPARK-011 trial comparing lenvatinib plus belzutifan with cabozantinib.

Dr. Monty Pal discusses the growing importance of quality of life and long-term tolerability when selecting subsequent therapies for advanced renal cell carcinoma (RCC).

Dr. Monty Pal discusses how patient- and disease-specific characteristics influence treatment sequencing decisions for advanced renal cell carcinoma (RCC) beyond the first-line setting.

Dr. Monty Pal discusses his approach to selecting second-line therapy for advanced renal cell carcinoma (RCC) based on the type of first-line immunotherapy regimen previously received.

Dr. Monty Pal begins the discussion on treatment sequencing in advanced renal cell carcinoma (RCC) by emphasizing the importance of optimizing first-line therapy, noting that many patients may not receive multiple subsequent lines of treatment.

Dr. Monty Pal summarizes his practical first-line treatment algorithm for advanced renal cell carcinoma (RCC), highlighting how he incorporates disease risk, clinical presentation, and treatment goals into routine decision making.

Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management of advanced renal cell carcinoma (RCC).

The panel discusses the full multidisciplinary team required to optimize outcomes for patients with ROS1-positive advanced NSCLC: neuro-oncology for brain metastasis management, radiation oncology for CNS and bone disease, palliative care and symptom management specialists from diagnosis, physical therapy and nutrition, social work, and mental health services.

The panel addresses patients who received crizotinib or entrectinib in first line rather than lorlatinib, and who are now progressing.

The panel reinforces that oligo-progression management in ROS1-positive NSCLC requires careful distinction from strategies used in EGFR-mutated NSCLC.

For the patient with a G2032R resistance mutation and intracranial progression, the panel unanimously favors lorlatinib-based therapy in second line based on its known activity against solvent-front mutations and documented CNS penetrance, with median duration of response of approximately 7 to 8 months in this setting.

The second clinical case presents a patient with ROS1 fusion-positive advanced NSCLC who achieved partial response on frontline lorlatinib, maintained for 18 months, before symptomatic and radiographic progression: increasing primary tumor size, new contralateral pulmonary nodules, and brain MRI showing 3 new small intracranial lesions.

Given the patient's osseous disease, the panel discusses bone-directed therapy integration.

All panelists select lorlatinib at 600 mg for this patient based on response rates, duration of disease control, favorable tolerability, and its design intent to achieve superior CNS penetration compared to earlier-generation ROS1 inhibitors, which is particularly relevant given the patient's age, symptomatic disease burden, and risk of future CNS progression.

The first clinical case presents a 58-year-old female never-smoker with persistent cough, mild dyspnea, and new right-sided pleural effusion.

The panel addresses scenarios where patients arrive on treatments other than the panel's preferred agent.

Beyond efficacy, the panel identifies the key factors influencing agent selection: brain metastasis activity given the high prevalence of CNS involvement in younger ROS1-positive patients; toxicity profiles (earlier agents cause significant dizziness, taste changes, and neuropathic pain that are poorly tolerated chronically); frequency of clinic visits; and insurance access.

Dr. Monty Pal compares the available immunotherapy plus tyrosine kinase inhibitor (IO/TKI) combination regimens for the first-line treatment of advanced renal cell carcinoma (RCC) and explains the clinical rationale behind his preferred treatment approach.

Dr. Monty Pal reviews how current clinical guidelines support both immunotherapy plus tyrosine kinase inhibitor (IO/TKI) combinations and dual immunotherapy (IO/IO) as frontline treatment options for advanced renal cell carcinoma (RCC).

Misako Nagasaka, MD, PhD, describes how it is a “great time to be a thoracic oncologist” with the constantly expanding armamentarium in the field. She specifically discusses the available treatment options in frontline EGFR mutation–positive advanced non–small cell lung cancer and what particular clinical and lifestyle benefits are provided by the treatment regimen of subcutaneous amivantamab plus lazertinib.

Misako Nagasaka, MD, PhD, discusses practical considerations for oncologists implementing subcutaneous (SC) vs intravenous (IV) amivantamab plus lazertinib in the frontline setting for patients with EGFR-mutated advanced or metastatic non–small cell lung cancer. Nagasaka recommends the SC over the IV regimen in the frontline setting, particularly when focusing on convenience and patients’ quality of life.